Polymerase chain reaction-triggered preemptive or deferred therapy to control cytomegalovirus-associated morbidity and costs in renal transplant patients

Preventing Post–Organ Transplantation Cytomegalovirus Disease with Ganciclovir: A Meta‐Analysis Comparing Prophylactic and Preemptive Therapies

“…Some trials enrolled subjects at the onset of CMV detection [40][41][42][43][44][45], whereas others enrolled subjects at the time of transplant [39,46,47]. Because trials using both methods were included in this study, a subgroup analysis of trials using each method was performed.…”

“…Subgroup analyses were performed on studies using each of these methods, and the analyses were compared to determine whether either method would significantly affect outcome data. [39][40][41][42][43][44][45][46][47] met the inclusion criteria for analysis (figure 1). One prospective head-to-head trial was identified that is not included in the meta-analysis, but it will be discussed later [13].…”